• Submission

Journal of Pharmaceutical Research International

  • About
    • About the Journal
    • Submissions & Author Guideline
    • Articles in Press
    • Editorial Policy
    • Editorial Board Members
    • Reviewers
    • Propose a Special Issue
    • Reprints
    • Subscription
    • Membership
    • Publication Ethics and Malpractice Statement
    • Digital Archiving Policy
    • Contact
  • Archives
  • Indexing
  • Publication Charge
  • Books
  • Testimonials
Advanced Search
  1. Home
  2. Archives
  3. 2020 - Volume 32 [Issue 40]
  4. Minireview Article

Submit Manuscript


Subscription



  • Home Page
  • Author Guidelines
  • Editorial Board Member
  • Editorial Policy
  • Propose a Special Issue
  • Membership

The Prospect of Treating Alzheimer Disease through Sleep

  • Jin Huang

Journal of Pharmaceutical Research International, Page 49-53
DOI: 10.9734/jpri/2020/v32i4031032
Published: 11 January 2021

  • View Article
  • Download
  • Cite
  • References
  • Statistics
  • Share

Abstract


Alzheimer's disease is caused by the deposition of amyloid and Tau proteins. These two proteins are present in normal brain cells, but in Alzheimer's disease, they accumulate in large quantities, affecting how brain cells function normally. The result is that brain cells can't communicate properly, leading to memory loss. The current treatment for Alzheimer's disease is mostly controlled by drugs. The three main drugs are Donepezil, Rivastigmine, and Galantamine, Reminyl. However, it has limited side effects and usually manifests as gastrointestinal distress. One of the functions of sleep is to accelerate the removal of amyloid in the brain, which can effectively improve the accumulation of amyloid and Tau proteins.


Keywords:
  • AD
  • amyloid & tau proteins
  • sleep deprivation
  • sleep disorders
  • sleep-rhythm
  • Full Article - PDF
  • Review History

How to Cite

Huang, J. (2021). The Prospect of Treating Alzheimer Disease through Sleep. Journal of Pharmaceutical Research International, 32(40), 49-53. https://doi.org/10.9734/jpri/2020/v32i4031032
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver

References

William James Deardorff. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease; 2016. Available:https://www.ncbi.nlm.nih.gov

Cochrane. Cognitive training therapy. Available:https://www.cochrane.org/zh-hans/evidence

Neurodegener Dis Manag. The sleep–wake cycle and Alzheimer’s disease; 2015. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257134/

Alzheimer's Association. Alzheimer's disease facts and figures; 2019. Available:https://www.sciencedirect.com/science/article/

Shi Y, Yamada K, Liddelow, S. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy, ApoE4 markedly exacerbates tau-mediated neurode generation in a mouse model of tauopathy. Nature. 2017;549:523–527. Available:https://www.nature.com/articles/nature24016

Michala Kolarova. Structure and pathology of tau protein in alzheimer disease; 2012. Available:https://doi.org/10.1155/2012/731526

Ann Neurol. Effect of sleep on overnight CSF amyloid-β kinetics; 2019. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876097/

Alzheimers. Treatments for Sleep Changes. Available:https://www.alz.org/alzheimers-dementia/treatments/for-sleep-changes

Cedernaes J, Osorio R. Candidate mechanisms for the association between sleep-wake disruption and Alzheimer's disease; 2017. Available:https://www.semanticscholar. org/paper/
  • Abstract View: 62 times
    PDF Download: 66 times

Download Statistics

Downloads

Download data is not yet available.
  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram
Make a Submission / Login
Information
  • For Readers
  • For Authors
  • For Librarians
Current Issue
  • Atom logo
  • RSS2 logo
  • RSS1 logo


© Copyright 2010-Till Date, Journal of Pharmaceutical Research International. All rights reserved.